Baird analyst Jeff Johnson raised the firm’s price target on Tandem Diabetes to $39 from $36 and keeps a Neutral rating on the shares. The firm noted the 2Q revenue upside/full-year guidance raise as early Mobi uptake is helping reverse last year’s sizable pump volume/revenue pressures.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- TNDM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Stifel sees Tandem underperformance as ‘overreaction’ after Mobi survey
- Tandem, DexCom announce t:slim X2 insulin pump authorized by Health Canada
- Citi opens ‘positive catalyst watch’ on Tandem Diabetes into earnings
- Tandem Diabetes Care Welcomes New EVP and COO